drugset / Trial / NCT00277576

Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection

NCT00277576 ↗

Phase 1 Completed 48 enrolled PowderMed
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to reduce hepatitis B disease.

Timeline

Start
2006-01
Primary completion
—
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject pPDPSC18 Vaccine — Other